Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
Chugai Pharmaceutical said on May 29 that it has filed a patent infringement lawsuit and a petition for a provisional disposition order against Sawai Pharmaceutical and Nichi-Iko Pharmaceutical, seeking to block the manufacturing and distribution of the copies of the…
To read the full story
Related Article
- Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
December 14, 2022
- Chugai Challenges Ruling in Method-of-Use Patent Case for Edirol
June 10, 2022
- Tokyo Court Nixes Chugai’s Method-of-Use Patent Claim for Edirol
May 30, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…